These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27025882)

  • 1. Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors.
    Montioli R; Voltattorni CB; Bertoldi M
    Curr Drug Metab; 2016; 17(5):513-8. PubMed ID: 27025882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
    Daidone F; Montioli R; Paiardini A; Cellini B; Macchiarulo A; Giardina G; Bossa F; Borri Voltattorni C
    PLoS One; 2012; 7(2):e31610. PubMed ID: 22384042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report.
    Radder DLM; Tiel Groenestege AT; Boers I; Muilwijk EW; Bloem BR
    J Parkinsons Dis; 2019; 9(2):437-439. PubMed ID: 30856121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
    Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M
    Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
    Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule.
    Lan J; Liu Z; Liao C; Merkler DJ; Han Q; Li J
    Curr Top Med Chem; 2019; 19(25):2318-2333. PubMed ID: 31629395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel inhibitors of human DOPA decarboxylase extracted from Euonymus glabra Roxb.
    Ren J; Zhang Y; Jin H; Yu J; Zhou Y; Wu F; Zhang W
    ACS Chem Biol; 2014 Apr; 9(4):897-903. PubMed ID: 24471650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.